Determinants of the quantity of hepatitis C virus RNA

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 844-851

  Thomas, David L ^a,b,e   Astemborski, Jacquie ^b   Vlahov, David ^b,c   Strathdee, Steffanie A ^b   Ray, Stuart C ^a   Nelson, Kenrad E ^b   Galai, Noya ^b   Nolt, Karen R ^a   Laeyendecker, Oliver ^a   Todd, John A ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NEW YORK ACADEMY OF MEDICINE   (United States)

^d BAYER CORPORATION   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ADULT; AGE; ARTICLE; BLOOD LEVEL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RNA ANALYSIS;

ADULT; AGED; AMINO ACID SEQUENCE; FEMALE; HEPACIVIRUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RNA, VIRAL; TIME FACTORS;

EID: 0034031613     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315314     Document Type: Article

References (43)

1. 1. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-6.
2. 2. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996; 335:1091-8.
3. 3. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177:40-7.
4. 4. Mellors JW, Rinaldo CRJ, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
5. 5. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4 cell count. JAMA 1998; 279:35-40.
6. 6. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352:1510-4.
7. 7. Evans JS, Nims T, Cooley J, et al. Serum levels of virus burden in early stage human immunodeficiency virus type 1 disease in women. J Infect Dis 1997; 175:795-800.
8. 8. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282:103-7.
9. 9. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-92.
10. 10. Gretch D, Corey L, Wilson J, et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high titer viremia correlates with advanced stage of disease. J Infect Dis 1994; 169:1219-25.
11. 11 De Moliner L, Pontisso P, De Salvo GL, Cavalletto L, Chemello L, Alberti A. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 1998; 42:856-60.
12. 12. Haydon GH, Jarvis LM, Blair CS, et al. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut 1998; 42:570-5.
13. 13. Negro F, Krawczynski K, Quadri R, et al. Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse transcriptase polymerase chain reaction. Hepatology 1999; 29:536-42.
14. 14. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study: a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991; 109:75-100.
15. 15. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35:3274-7.
16. 16. Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM, Nelson KE. Seroepidemiology of hepatitis B virus in a population of injecting drug users - association with drug injection patterns. Am J Epidemiol 1995; 142:331-41.
17. 17. Lau JY, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341:1501-4.
18. 18. Davidson F, Simmonds P, Ferguson JC, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol 1995; 76:1197-204.
19. 19. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29:908-14.
20. 20. Ray SC, Wang YM, Laeyendecker O, Ticehurst J, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as decoy. J Virol 1999; 73:2938-46.
21. 21. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996; 174:690-5.
22. 22. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 1994; 84:1020-3.
23. 23. Sherman KE, O'Brien J, Gutierrez G, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993; 31:2679-82.
24. 24. Telfer PT, Brown D, Devereux H, Lee CA, Dusheiko GM. HCV RNA levels and HIV infection: evidence fora viral interaction in haemophilic patients. Br J Haematol 1994; 88:397-9.
25. 25. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9:1131-6.
26. 26. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users in Baltimore. Medicine 1995; 74: 212-20.
27. 27. Hagiwara H, Hayashi N, Mita E, et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17:545-50.
28. 28. Koike K, Yasuda K, Yotsuyanagi H, et al. Dominant replication of either virus in dual infection with hepatitis viruses B and C. J Med Virol 1995;45: 236-9.
29. 29. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28:27-33.
30. 30. Pontisso P, Gerotto M, Ruvoletto MG, et al. Hepatitis C genotypes in patients with dual hepatitis B and C virus infection. J Med Virol 1996; 48:157-60.
31. 31. Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol 1998; 36:2084-6.
32. 32. Pontisso P, Ruvoletto MG, Fattovich G, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105:1529-33.
33. 33. Jarvis LM, Watson HG, McOmish F, Peutherer JF, Ludlam CA, Simmonds P. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 1994; 170:1018-22.
34. 34. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258:135-40.
35. 35. Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 20:1115-20.
36. 36. McGuinness PH, Bishop GA, Painter DM, Chan R, McCaughan GW. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology 1996; 23:676-87.
37. 37. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27:1717-22.
38. 38. Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP, Wilber JC. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 1998; 28:1702-6.
39. 39. Davis GL, Lau JYN, Urdea MS, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19:1337-41.
40. 40. Miskovsky EP, Carella AV, Gutekunst K, Sun C, Quinn TC, Thomas DL. Clinical characterization of a competitive PCR assay for quantitative testing of hepatitis C virus. J Clin Microbiol 1996; 34:1975-9.
41. 41. Chayama K, Tsubota A, Kobayashi M, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25:745-9.
42. 42. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-81.
43. 43. Hashimoto M, Chayama K, Kobayashi M, et al. Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region. J Med Virol 1999; 58:247-55.